Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

4,170 results
MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1974 1
1975 1
1976 2
1977 1
1978 2
1979 1
1980 11
1981 33
1982 56
1983 75
1984 52
1985 60
1986 55
1987 80
1988 56
1989 58
1990 76
1991 99
1992 104
1993 98
1994 108
1995 159
1996 110
1997 86
1998 113
1999 117
2000 134
2001 109
2002 129
2003 116
2004 136
2005 147
2006 140
2007 154
2008 115
2009 116
2010 175
2011 177
2012 172
2013 193
2014 173
2015 184
2016 176
2017 152
2018 132
2019 44
Text availability
Article attribute
Article type
Publication date

Search Results

4,170 results
Results by year
Filters applied: . Clear all
Page 1
Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Nelson AL. Expert Rev Clin Pharmacol 2017 - Review. PMID 28617060
A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. ...
A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. ...
Levonorgestrel-releasing intra-uterine systems as female contraceptives.
Grandi G, et al. Expert Opin Pharmacother 2018 - Review. PMID 29637798
INTRODUCTION: The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. ...
INTRODUCTION: The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. ...
Abnormal uterine bleeding in perimenopause
Goldstein SR and Lumsden MA. Climacteric 2017 - Review. PMID 28780893
The use of oral contraceptive pills especially those with a short hormone-free interval, the insertion of the levonorgestrel intrauterine system, the incorporation of newer medical therapies including antifibrinolytic drugs and selective progesterone receptor modulators and minimally invasive treatments have made outpatient therapy increasingly effective. ...
The use of oral contraceptive pills especially those with a short hormone-free interval, the insertion of the levonorgestrel intrauterine system, the incorporation of newer medical therapies including antifibrinolytic drugs and selective progesterone receptor modulators and minimally invasive …
The levonorgestrel-releasing intrauterine device potentiates stress reactivity.
Aleknaviciute J, et al. Psychoneuroendocrinology 2017. PMID 28315609
BACKGROUND: The levonorgestrel-releasing intrauterine device (LNG-IUD) is currently recommended as a first-line contraceptive with an exclusively local intrauterine influence. ...For each study, women were included from three groups: LNG-IUD (0.02mg/24h), oral ethinylestradiol/levonorgestrel (0.03mg/0.15mg; EE30/LNG) and natural cycling (NC). ...
BACKGROUND: The levonorgestrel-releasing intrauterine device (LNG-IUD) is currently recommended as a first-line contraceptive with an exclusively local intrauterine influence. ...For each study, women were included from three groups: LNG-IUD (0.02mg/24h), oral ethinylestradiol/levonorgestr
The safety of intrauterine devices among young women: a systematic review
Jatlaoui TC, et al. Contraception 2017 - Review. PMID 27771475 Free PMC article.
Two studies (Level II-2, fair) examined risks of expulsion among younger compared with older women using levonorgestrel-releasing (LNG-) IUDs; one reported no difference in expulsion, while the other reported increased odds for younger women. ...
Two studies (Level II-2, fair) examined risks of expulsion among younger compared with older women using levonorgestrel-releasing (LNG-) IUDs; one reported no difference in expulsion, while the other reported increased odds for younger women. ...
Effects of Levonorgestrel and progesterone on Oviductal physiology in mammals.
Li C, et al. Reprod Biol Endocrinol 2018. PMID 29925391 Free PMC article.
However, levonorgestrel and progesterone reduced the ciliary beat frequency in fallopian tubes in a dose-dependent manner. An in vivo model also showed that levonorgestrel and progesterone could lead to embryo retention in the oviducts. CONCLUSIONS: These findings show that levonorgestrel and progesterone can reduce the ciliary beat frequency without altering receptivity, indicating a possible mechanism for progesterone- or levonorgestrel-induced tubal pregnancy....
However, levonorgestrel and progesterone reduced the ciliary beat frequency in fallopian tubes in a dose-dependent manner. An in vivo model also showed that levonorgestrel and progesterone could lead to embryo retention in the oviducts. CONCLUSIONS: These findings show that levonorg
Non-contraceptive benefits of intrauterine levonorgestrel administration: why not?
Sabbioni L, et al. Gynecol Endocrinol 2017 - Review. PMID 28586290
Levonorgestrel intrauterine systems (LNG-IUS) represent a modern therapy for an array of preexisting gynecological conditions, though they were first marketed in Finland in 1990. ...This manuscript describes the possible reasons for this misuse, taking in consideration the clinical noncontraceptive benefits of intrauterine levonorgestrel in routinary practice. ...
Levonorgestrel intrauterine systems (LNG-IUS) represent a modern therapy for an array of preexisting gynecological conditions, though they were first marketed in Finland in 1990. ...This manuscript describes the possible reasons for this misuse, taking in consideration the clinical noncontrac
Continuation of copper and levonorgestrel intrauterine devices: a retrospective cohort study.
Phillips SJ, et al. Am J Obstet Gynecol 2017. PMID 28315664 Free PMC article.
At 4 years, continuation rates were 45.1% for levonorgestrel intrauterine device and 32.6% for copper intrauterine device (P < .01), and at 5 years continuation rates were 28.1% for levonorgestrel intrauterine device and 23.8% for copper intrauterine device (P = .33). ...Copper intrauterine device users were more likely to experience expulsion (10.2% copper intrauterine device vs 4.9% levonorgestrel intrauterine device, P < .01) over the study period and to become pregnant in the first year of use (1.6% copper intrauterine device vs 0.1% levonorgestrel intrauterine device, P < .01). ...

At 4 years, continuation rates were 45.1% for levonorgestrel intrauterine device and 32.6% for copper intrauterine device (P < .01), and at 5 years continuation rates were 28.1% for levonorgestrel intrauterine device and 23.8% for copper intrauterine device (P = .33). ...Copper intr

Emergency Contraception
Batur P, et al. Mayo Clin Proc 2016 - Review. PMID 27261868
Although ulipristal acetate requires a provider's prescription, oral levonorgestrel (LNG) is available over the counter for women of all ages. ...
Although ulipristal acetate requires a provider's prescription, oral levonorgestrel (LNG) is available over the counter for women of all ages. ...
Progestin and breast cancer risk: a systematic review
Samson M, et al. Breast Cancer Res Treat 2016 - Review. PMID 26700034 Free PMC article.
Five of the six studies reported no association between progestin-only formulations (including norethindrone oral contraceptives, depot medroxyprogesterone acetate, injectable, levonorgestrel system users, implantable and intrauterine devices) and breast cancer risk. ...
Five of the six studies reported no association between progestin-only formulations (including norethindrone oral contraceptives, depot medroxyprogesterone acetate, injectable, levonorgestrel system users, implantable and intrauterine devices) and breast cancer risk. ...
4,170 results
Jump to page
Feedback